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Glutamine is a central nutrient for many cancers, contributing to the generation of
building blocks and energy-promoting signaling necessary for neoplastic prolifera-
tion. In this study, we hypothesized that lowering systemic glutamine levels by ex-
ercise may starve tumors, thereby contributing to the inhibitory effect of exercise
on tumor growth.We demonstrate that limiting glutamine availability, either phar-
macologically or physiologically by voluntary wheel running, significantly attenu-
ated the growth of two syngeneic murine tumor models of breast cancer and
lung cancer, respectively, and decreased markers of atrophic signaling in muscles
from tumor-bearing mice. In continuation, wheel running completely abolished tu-
mor-induced loss of weight and lean body mass, independently of the effect of
wheel running on tumor growth. Moreover, wheel running abolished tumor-
induced upregulation of muscular glutamine transporters and myostatin signaling.
In conclusion,ourdata suggest that voluntarywheel runningpreservesmusclemass
by counteractingmuscular glutamine releaseand tumor-inducedatrophic signaling.
INTRODUCTION
Tumors are avid glutamine consumers, and the versatile functions of glutamine within the cell make it a cen-
tral nutrient for many cancers. After import, glutamine can donate its carbons for synthesis of amino acids
and fatty acids and its nitrogen to synthesis of nucleotides, thereby directly supporting the accumulation of
cellular building blocks (Altman et al., 2016; DeBerardinis and Cheng, 2010; Hensley et al., 2013). Glutamine
also supports the generation of cellular energy, as it can be metabolized via glutamate to a-ketoglutarate,
providing substrates for the citric acid cycle and ATP formation (Altman et al., 2016; DeBerardinis and
Cheng, 2010). Furthermore, glutamine regulates cell signaling, as it can be rapidly exported out of the
cell in exchange for essential amino acids that directly activate mTOR, thereby inducing protein translation
and cell growth (Altman et al., 2016; DeBerardinis and Cheng, 2010; Hensley et al., 2013).
The pleiotropic role of glutamine in cancer cells has made glutamine uptake and metabolism attractive
therapeutic targets, and several pharmacological approaches to limiting glutamine uptake and meta-
bolism in tumor cells have been undertaken. Inhibition of the glutamine transporters SLC1A5 (Chiu
et al., 2017; Schulte et al., 2018) and SLC7A5 (Ha¨fliger et al., 2018) and various steps in glutaminolysis
(glutaminase (Gross et al., 2014), aminotransferases (Korangath et al., 2015) as well as glutamate dehydro-
genase (Jin et al., 2015)) have all displayed anti-tumor activity in preclinical models. These approaches
share a tumor-centric methodology, interfering at the level of the tumor cell.
Glutamine is the most abundant amino acid in the circulation, constituting around 20% of the free amino
acid pool (Altman et al., 2016). More than 70% of the circulating glutamine derives from skeletal muscle
(Nurjhan et al., 1995) where it is either released from proteins by proteolysis or through de novo synthesis
by glutamine synthetase (GS) (Felig et al., 1973; Garber et al., 1976; Kuhn et al., 1999; Schrock et al., 1980).
Other tissues such as lung (Plumley et al., 1990), liver (Souba et al., 1988), and adipose tissue (Patterson
et al., 2002) also have the capacity for glutamine release, yet their contributions to the plasma glutamine
pool are under normal conditions modest. The majority of glutamine consumed in the diet is retained
by cells in the intestinal mucosa and does not reach the circulation (Biolo et al., 1995; Wu, 1998). Thus,
release from skeletal muscle is the primary source of glutamine in serum.iScience 23, 100978, April 24, 2020 ª 2020 The Authors.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ArticleExercise has the potential to regulate serum glutamine levels, yet the effect depends on the intensity and
duration of the exercise intervention. Acute exercise and mild/moderate exercise interventions have
yielded varying results, whereas substantial documentation exists for reduced serum glutamine levels after
prolonged or strenuous exercise (Agostini and Biolo, 2010; Castell and Newsholme, 1998; Henriksson,
1991; Keast et al., 1995). The mechanism behind this observation is not completely understood but could
be explained by reduced glutamine synthesis in the muscle, reduced glutamine release from muscle, or by
increased glutamine uptake by other tissues (dos Santos et al., 2009).
During the 90s, it was hypothesized that exercise-induced lowering of plasma-glutamine could explain
post-exercise immune changes (Newsholme and Calder, 1997). Glutamine intervention studies did, how-
ever, not restore exercise-induced immune perturbations (Hiscock and Pedersen, 2002). Here, we suggest
that glutamine may represent a possible link between exercise and cancer. By lowering serum glutamine,
exercise might represent a non-pharmacological approach to limiting the access of tumor cells to an
important nutrient.
In this study, we hypothesized that lowering serum glutamine levels by exercise might starve tumors of
glutamine, thereby contributing to the inhibitory effect of exercise on tumor growth.RESULTS
Systemic Glutamine Availability Controls Tumor Growth
To investigate the importance of circulating glutamine levels for tumor growth, we limited the access of
tumors to glutamine by treating tumor-bearing mice with methionine sulfoximine (MSO), a pharmacolog-
ical inhibitor of glutamine synthetase (GS). We used two different syngeneic murine cancer models, Lewis
lung carcinoma (LLC) and triple-negative breast cancer (E0771), which both harbor mutations in Kras (Aga-
lioti et al., 2017; Yang et al., 2017) known to be associated with glutamine dependence (Gaglio et al., 2011),
and which both showed markedly reduced cell proliferation when cultured in medium lacking glutamine
(Figures 1A and 1F). In the tumor-bearing mice, MSO administration significantly lowered serum glutamine
levels in mice with both tumor types (LLC: 57%, p < 0.001, Figure 1B; and E0771: 48%, p < 0.001, Fig-
ure 1G) and inhibited tumor growth as quantified by both tumor weight (LLC:58%, p < 0.01, Figure 1C;
and E0771:34%, p = 0.11, Figure 1H) and tumor volume (LLC:62%, p < 0.01, Figure 1D; and
E0771:44%, p = 0.056, Figure 1I). For both tumor types, serum glutamine concentration significantly
correlated with tumor weight (Figures 1E and 1J).MSO Treatment Regulates Glutamine Metabolism and Atrophic Signaling
LLC-tumor-bearing mice treated with MSO exhibited a significant intratumoral upregulation of the expres-
sion of glutamine transporters SLC1A5 (+83%, p < 0.001) and SLC7A5 (3-fold, p < 0.001) (Figure 2A), sug-
gesting that these tumors attempt to maintain sufficient glutamine supply by increasing the number
of transporters once serum glutamine levels become scarce. Of note, GS expression was not induced
by MSO, suggesting that these tumors rely heavily on external glutamine supply. In tibialis anterior muscle
of the samemice, MSO treatment strongly upregulatedGS (+82%, p < 0.01) and the glutamine transporters
SLC1A5 (+56%, p < 0.01) and SLC38A3 (+53%, p < 0.001) (Figure 2B), reflecting a compensation for the in-
hibition of GS activity. Interestingly, blocking glutamine synthesis also resulted in reduced intramuscular
expression of the atrophy marker atrogin-1 (44%, p < 0.001) (Figure 2C) and activin signaling, i.e. activin
receptor 2A (AR2A) (12%, p < 0.001) and activin receptor 2B (AR2B) (39%, p < 0.001) (Figure 2D), sug-
gesting a link between glutamine metabolism and muscle wasting/maintenance. However, we did not
detect any tumor-induced weight loss in this experiment (Figure 2E).Acute and Long-Term Exercise Training Regulates Glutamine Availability and Metabolism
A physiological way to reduce circulating glutamine levels is through exercise. In accordance, we found
that 45 min of swimming in untrained and exercise-trained (access to running wheels for four weeks) tu-
mor-free C57BL/6 mice induced an acute drop (27% for untrained mice, p < 0.01, and 39% for trained
mice, p < 0.001) in serum glutamine concentration, which persisted at least 2 h after the intervention
(Figure 3A). Similarly, mice with E0771 tumors exhibited reduced serum glutamine concentration (27%,
p < 0.001) 2 h after a 45 min swimming intervention compared with a group of tumor-bearing control
mice that did not swim (Figure 3B). Serum glutamine levels in mice sampled 24 and 48 h after swimming
did not differ from the control group.2 iScience 23, 100978, April 24, 2020
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Figure 1. Reduced Access to Glutamine Inhibits Cancer Growth In Vitro and In Vivo
Cell proliferation of murine lung cancer (Lewis Lung carcinoma [LLC]) (A) and breast cancer (E0771) (F) cells in growth medium with and without glutamine.
Data represent absorbance at 490 nm after an MTS assay. Serum glutamine levels in mice with LLC tumors with and without MSO treatment (B) (CON = 14,
MSO = 14, unpaired Student’s t-test). Size at takedown (tumor growth for 16 days) of LLC tumors from mice with and without MSO treatment quantified by
weight (C) and volume (D) (CON = 14, MSO = 14, unpaired Student’s t-tests). Pearson correlation (E) of LLC tumor weight and serum glutamine levels. Serum
glutamine levels in mice with breast cancer (E0771) tumors with and without MSO treatment (G) (CON = 12, MSO = 12, unpaired Student’s t-test). Size at
takedown (tumor growth for 16 days) of E0771 tumors frommice with and without MSO treatment quantified by weight (H) and volume (I) (CON = 12, MSO =
12, unpaired Student’s t-tests). Pearson correlation (J) of breast cancer (E0771) tumor weight and serum glutamine levels. Data are depicted as means +/
SD. *p < 0.05, **p < 0.01, ***p < 0.001.
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synthesis and transport. In mice with E0771 tumors, the reduction in serum glutamine 2 h after swimming coin-
cided with increased intramuscular expression of GS (+45%, p < 0.01), SLC7A5 (4-fold, p < 0.001) and SLC38A3
(+21%, p < 0.05) (Figure 3C). In mice sampled after 24 h, SLC38A3 expression was significantly reduced (20%,
p < 0.05) compared with controls, whereas GS, SLC1A5, and SLC7A5 were not significantly altered (Figure 3C).
In tumors from these mice, we observed modest regulation of the expression of GS (+17%, p < 0.05) and
SLC7A5 (+17%, p < 0.05) 2 h after the swimming intervention, whereas SLC1A5 and SLC38A3 did not differ
from control levels (Figure 3D). After 24 and 48 h no differences were detected (Figure 3D). This suggests
that acute exercise directly impacts glutamine synthesis and transport in tumor and muscle tissue with roughly
the same pattern but to a larger extent in the muscles.
We went on to investigate the effect of long-term training. C57BL/6 mice were randomized to cages with
and without running wheels for four weeks and subsequently inoculated with E0771 tumors. Voluntary
wheel running significantly reduced tumor growth compared with control mice as quantified by tumor
weight (43%, p < 0.01, Figure 3E) and tumor volume (42%, p < 0.01, Figure 3F). Serum glutamine levels
obtained at termination of the experiment did not differ between control and wheel running miceiScience 23, 100978, April 24, 2020 3
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Figure 2. Blocking GS Activity Affects Glutamine Metabolism and Transport and Atrophic Signaling in Tumors
and Muscle
Expression of genes involved in glutamine transport and metabolism in LLC tumors from mice with and without MSO
treatment (A) (CON = 13, MSO = 13, unpaired Student’s t-tests). Gene expression of glutamine synthetase (GS) and
glutamine transporters (B), atrophy markers (C), and myostatin signaling cascade (D) in tibialis anterior muscle from mice
with LLC tumors with and without MSO treatment (CON = 13, MSO = 13, unpaired Student’s t-tests). Change in body
weight (excluding tumor weight) in the period of tumor challenge (tumor growth for 16 days) in mice with LLC tumors with
and without MSO treatment (E) (CON = 14, MSO = 14, paired Student’s t-tests of weight at tumor induction and
takedown). Data are depicted as means +SD. *p < 0.05, **p < 0.01, ***p < 0.001.
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Article(Figure 3G). Muscles fromwheel-runningmice had significantly reduced expression of GS (46%, p < 0.001)
and the glutamine transporters SLC1A5 (29%, p < 0.001) and SLC38A3 (41%, p < 0.001) (Figure 3H)
compared with controls, suggesting that exercise resulted in a long-term adaptive suppression of the
expression of GS and glutamine transporters in muscles.
Voluntary Wheel Running Prevents Tumor-Induced Weight Loss
Next, we set out to investigate muscle maintenance in a cachexia-inducing tumor type. C57BL/6 mice
were randomized to cages with and without running wheels, and after four weeks inoculated with LLC
cells. Wheel running significantly reduced tumor growth in this tumor model as quantified by both tumor
weight (90%, p < 0.01, Figure 4A) and tumor volume (91%, p < 0.01, Figure 4B). In order to shed light on
the pronounced tumor growth suppression in this mouse model, we opted to perform RNA sequencing
to elucidate genome-wide regulation in the tumors. RNA sequencing of LLC tumor tissue revealed virtually
no differential regulation of intratumoral gene expression between tumors from the control and exercise
groups as evidenced by principal component analyses (Figures 4C and S1 and Table S1). Accordingly,
targeted PCR against glutamine transporters found no significant differences in the expression patterns
in LLC tumors in response to voluntary wheel running (Figure 4D).
The LLC-tumor-bearing mice exhibited a significant weight loss in the period of tumor burden (1.14 g,
p < 0.01), which was completely prevented by wheel running (p < 0.01 for interaction in a two-way
ANOVA) (Figure 4E). The increase in lean body mass in the period of tumor burden observed across the4 iScience 23, 100978, April 24, 2020
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Figure 3. Acute Swimming Reduces Serum Glutamine and Voluntary Wheel Running Reduces Tumor Growth and Affects Glutamine Synthesis and
Transport in Muscle and Tumor
Serum glutamine levels (A) from trained and untrained mice (+/ 4 weeks of voluntary wheel running) sampled before (CON), immediately after (0), and 2 h
into the recovery (2) of a 45-min swimming intervention (untrained = 9, trained = 7, two-way ANOVA with repeated measures, Bonferroni correction). Serum
glutamine levels (B) from four groups of mice with E0771 tumors, taken down at the indicated time points after a 45-min swimming intervention (CON = 9,
2 h = 10, 24 h = 10, 48 h = 9, one-way ANOVA with Bonferroni correction). Gene expression of GS and glutamine transporters (C) in tibialis anterior muscle
frommice in (B) (one-way ANOVA with Bonferroni correction). Gene expression of GS and glutamine transporters (D) in E0771 tumors from the samemice as
in (B) (one-way ANOVAwith Bonferroni correction). Size at takedown (tumor growth for 15 days) of E0771 tumors quantified by weight (E) and volume (F) from
sedentary (CON) and wheel running (EX) C57BL/6 mice (CON = 18, EX = 18, unpaired Student’s t-tests). Serum glutamine levels (G) in mice from E and F
(CON= 18, EX = 18, unpaired Student’s t-tests). Gene expression of GS and glutamine transporters (H) in tibialis anterior muscle frommice in E and F (CON=
16, EX = 14, unpaired Student’s t-tests). Data are depicted as means +/ SD, *p < 0.05, **p < 0.01, ***p < 0.001.
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normalized by wheel running (Figure 4F). Tumor-free mice exhibited reductions in fat mass but in the
same period an increase in lean body mass (Figure 4G).
When exploring the muscular signaling in these mice, we found that LLC tumors induced the
mRNA expression of SLC7A5 (+57%, p < 0.01) and tended to induce the expression of SLC1A5 (+16%,
p = 0.093) (Figure 4I). This induction of glutamine transporters by LLC tumors was abolished by wheel
running (Figure 4I). In continuation, the presence of LLC tumors induced the expression of the atrophy
markers atrogin-1 (+50%, p < 0.05) and MuRF1 (+63%, p < 0.05) (Figure 4J) and myostatin signaling
(myostatin: +57%, p < 0.001, activin receptor 2A: +26%, p < 0.001, and SMAD3: +73%, p < 0.001)
(Figure 4H). These inductions were completely abolished with wheel running (Figures 4H and 4J), consis-
tent with the observed weight loss and impaired gain of lean mass. No statistically significant differences
were observed in the muscular protein expression of GS, the glutamine transporter SLC38A3, or the at-
rophy markers atrogin-1 and Murf1 (Figure 4K).
Wheel Running Prevents Tumor-Induced Weight Loss Independently of Tumor Size
Because wheel running had a marked effect on tumor growth, we confirmed the effect of voluntary
wheel running on tumor-induced weight loss and intramuscular signaling in a separate experiment whereiScience 23, 100978, April 24, 2020 5
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Figure 4. Voluntary Wheel Running Reduces Tumor Growth and Prevents Tumor-Induced Weight Loss and Intramuscular Changes in Glutamine
Transport and Catabolic Signaling
Size at takedown (tumor growth for 23 days) of LLC tumors quantified by weight (A) and volume (B) from sedentary and wheel running C57BL/6 mice (CON =
8, EX = 13, unpaired Student’s t-tests). Principal Component Analysis of intratumoral gene expression profiles (C) obtained by RNA-sequencing of tumors in
(A and B) (see also Figure S1 and Table S1). Gene expression of GS and glutamine transporters (D) in tumors in (A and B). Change in body weight in the period
of tumor challenge (tumor growth for 23 days) (E) in sedentary and wheel-running C57BL/6 mice with and without LLC tumors (no tumor = 12, CON = 8, no
tumor + EX = 10, EX = 13, two-way ANOVAwith Bonferroni correction, p = 0.003 for interaction. $ indicates a statistically significant weight change in a paired
Student’s t-test of weight at tumor induction and takedown). Percentage change in lean body mass (F) and fat mass (G) during tumor challenge obtained by
DXA scanning of mice from Figure E prior to tumor induction and at takedown (tumor growth for 23 days) (two-way ANOVA with Bonferroni correction. $
indicates a statistically significant change in lean body mass and fat mass in a paired Student’s t-test of lean and fat mass at tumor induction and takedown).
Gene expression of myostatin signaling cascade (H), GS, and glutamine transporters (I) and atrophy markers (J) in tibialis anterior muscle of mice from (E)
(two-way ANOVA with Bonferroni correction, p-values for interaction: myostatin = 0.0096, SMAD3 = 0.092, SMAD7 = 0.019, SLC1A5 = 0.017, atrogin-1 =
0.058, MuRF1 = 0.042). Protein expression of GS, glutamine transporters, and atrophy markers (K) in gastrocnemius muscle of mice from (E). Data represent
fold changes in Western blot band intensity. The signal for the protein of interest in each lane was normalized to the total protein amount in the same lane.
Data represent the mean of two independent experiments (two-way ANOVA with Bonferroni correction). Representative Western blot images (L) of GS,
glutamine transporters, and atrophy markers quantified in (K). Data are depicted as meanG SD. *p < 0.05, **p < 0.01, ***p < 0.001, $ p < 0.05, $$ p < 0.01.
ll
OPEN ACCESS
iScience
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groups of mice with the same average tumor size (Figures 5A and 5B). In line with the previous experiment,
LLC tumors induced a significant weight loss of 1.13 g (p < 0.01), which was completely abolished by
voluntary wheel running (Figure 5C), despite similar tumor burden in the control and exercise groups. In6 iScience 23, 100978, April 24, 2020
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Figure 5. Voluntary Wheel Running Prevents Tumor-Induced Weight Loss and Regulates Intramuscular Signaling Independently of Tumor Size
Size at takedown of LLC tumors quantified by weight (A) and volume (B) from sedentary and wheel running C57BL/6 mice (CON = 10, EX = 23, unpaired
Student’s t-tests) (mean period of tumor growth: CON = 23.3 days +/ 4.09, EX = 23.5 days +/4.9). Change in body weight in the period of tumor challenge
(excluding tumor weight) (C) in mice from (A and B) (CON = 10, EX = 23, unpaired Student’s t-test. $ indicates a statistically significant weight change in a
paired Student’s t-test of weight at tumor induction and takedown). Linear regression (D) of tumor weight versus change in body weight in mice from (A and
B). Gene expression of GS and glutamine transporters (E), atrophy markers (F), and myostatin signaling cascade (G) in tibialis anterior muscle frommice in (A
and B) (CON = 10, EX = 21, unpaired student’s t test). Data are depicted as mean G SD. *p < 0.05, **p < 0.01, ***p < 0.001, $ p < 0.05, $$ p < 0.01.
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correlation was abolished in the wheel running group. As before, the intramuscular expression levels of
glutamine transporters SLC1A5 (15%, p = 0.053) and SLC7A5 (32%, p < 0.05) (Figure 5E), as well
as the atrophy marker MuRF1 (52%, p < 0.05) (Figure 5F) and myostatin signaling (myostatin: 31%,
p < 0.01, and SMAD3:20%, p < 0.01) (Figure 5G) were reduced by wheel running, suggesting that the
regulation by wheel running can overcome the tumor-induced changes independently of tumor size.Global Gene Expression in Muscles
Given the protection against tumor-induced weight loss by wheel running, we explored intramuscular
exercise adaptations in response to voluntary wheel running. RNA sequencing of muscle tissue from the
mice with similarly sized LLC tumors showed significant changes in the muscular transcription of 265 genes
and a clear separation between the control and exercise groups by principal component analysis (Figures
6A and S2 and Table S2). Subsequent pathway analysis revealed that the upregulated genes were mostly
associated to myogenesis and oxidative phosphorylation (Figure 6B), demonstrating that mice with access
to running wheels exhibited classical intramuscular exercise adaptations despite LLC tumor burden. Inter-
estingly, genes related to alternative splicing were also identified in the pathway analysis (Figure 6C). In
support of these findings, we measured the splice variants of PGC-1a, which demonstrated differential
expression with wheel running and tumor burden (Figure 6D).iScience 23, 100978, April 24, 2020 7
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Figure 6. Voluntary Wheel Running Induces Classical Intramuscular Exercise Adaptations in Tumor-Bearing Mice
Principal component analysis of intramuscular gene expression profiles (A) obtained by RNA-sequencing of tibialis
anterior muscle frommice in Figures 5A and 5B (CON = 10, EX = 14 [samples selected based on which mice ran the most])
(see also Figure S2 and Table S2). Heatmaps of ranks for hallmark (B) and Kyoto Encyclopedia of Genes and Genomes
(KEGG) (C) gene-sets associated with genes significantly downregulated (left column), upregulated (right column), or
regulated independently of direction (middle column) in muscle tissues from mice in Figures 5A and 5B. Only the 11 top
ranked (most regulated) gene-sets are shown (out of 50 for hallmarks pathways, out of 186 for KEGG). The more red the
color, the higher the rank. Gene expression of PGC-1a splice variants (D) in tibialis anterior muscle frommice in Figure 5E;
n.d., not detectable. Data are depicted as mean +SD. *p < 0.05, **p < 0.01, ***p < 0.001.
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Across themurine studies, weobserved concurrent regulation of glutaminemetabolismandmyostatin/atrophy
signaling. Thus, to explore any co-regulation we investigated the effect of myostatin stimulation and reduced
glutamine availability on the expression of glutamine transporters in C2C12 myotubes. In accordance with
others (Zhang et al., 2017) we found that differentiation of C2C12myotubes inmedium conditioned by cultured
LLC cells yielded visibly thinner myotubes compared with C2C12 grown under control conditions (Figure 7A).
To investigate if tumor-derivedmyostatinmight be responsible for the tumor-induced expression of glutamine
transporters in muscle observed in the murine studies, we stimulated fully differentiated C2C12 myotubes with
recombinant myostatin (400 ng/mL) for 2.5 h. Myostatin reduced the expression of GS (15%, p < 0.001),
SLC1A5 (7%, p = 0.07), and SLC7A5 (9%, p < 0.01) (Figure 7B), suggesting that the tumor-induced upregu-
lation of glutamine transporters in muscle is not driven by myostatin.
Next, we exposed fully differentiated C2C12 myotubes to reduced glutamine availability in the cell
medium. Compared with standard cell medium conditions (3.9 mM glutamine), 2.5 h of incubation in
medium with 0.5 mM glutamine reduced the expression levels of GS (9%, p < 0.01), SLC1A5 (17%,
p < 0.001), and SLC7A5 (33%, p < 0.001) (Figure 7C), whereas complete glutamine depletion for 2.5 h
reduced the expression of GS (10%) and induced the expression of SLC1A5 (+32%, p < 0.001) and
SLC7A5 (57%, p < 0.001) (Figure 7C). This suggests that external glutamine availability regulates the expres-
sion of glutamine transporters in myotubes. Incubation of C2C12 cells in medium with 0.5 mM glutamine
did not significantly affect the expression of atrophy markers (Figure 7D) or myostatin (Figure 7E) but
reduced the expression of activin receptor 2A (8%, p < 0.05), activin receptor 2B (12%, p < 0.01), and
SMAD3 (13%, p < 0.001) (Figure 7D). Complete glutamine depletion for 2.5 h induced the expression
levels of atrogin-1 (+12%, p < 0.05), tended to induce MuRF1 (+13%, p = 0.09) (Figure 7D), and induced
activin receptor 2A (+8%, p < 0.05), SMAD2 (+13%, p < 0.05), and SMAD7 (+22%, p < 0.01) (Figure 7E).DISCUSSION
Here, we demonstrate that reducing glutamine availability, through either pharmacological treatment or
voluntary wheel running, significantly attenuated the growth of two different syngeneic murine tumor
models, respectively the triple-negative breast cancer model E0771 and the lung cancer model LLC.
Both interventions decreased intramuscular mRNA expression of atrophy markers in tumor-bearing
mice, resulting in a complete prevention of LLC tumor-induced weight loss with wheel running. Thus,
our studies suggest that voluntary wheel running may preserve muscle mass in mice despite a large tumor
burden by counteracting atrophic signaling and muscular glutamine release.
Regulation of tumor growth by limiting glutamine utilization has previously focused on drugs targeting
intratumoral metabolism. Here, we aimed to regulate glutamine availability by addressing the systemic
production. MSO treatment inhibits GS activity and in our study lowered glutamine levels in serum
by approximately 50%. This markedly correlated with reduced growth of the two investigated tumor
models, underscoring that tumor growth might be controlled by reducing glutamine availability. As a
consequence, we observed that LLC tumors upregulated SLC1A5 and SLC7A5 expression. These two
glutamine transporters are believed to be functionally coupled in tumors ensuring both glutamine import
for intracellular glutaminolysis and export in exchange for essential amino acids and activation of cell
growth via mTOR (Bhutia and Ganapathy, 2016). Upregulation of this transport system by MSO likely
reflects a compensatory response by tumors to the reduced glutamine availability. In muscle tissue from
LLC-tumor-bearing mice, we observed a significant reduced expression of the atrophy marker atrogin-1
and activin receptor 2A and 2B after MSO treatment, suggesting a link between glutamine metabolism
and muscle wasting/maintenance.iScience 23, 100978, April 24, 2020 9
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Figure 7. Co-regulation of Glutamine and Myostatin
Representative pictures of C2C12 myotubes differentiated under control conditions or in 25% medium conditioned by
LLC cells, stained for a-actinin (A). Gene expression of GS and glutamine transporters (B) in fully differentiated C2C12
myotubes after 2.5 h incubation with or without myostatin (400 ng/mL) (n = 8, unpaired Student’s t-test). Gene expression
of GS and glutamine transporters (C), atrophy markers (D), and myostatin signaling cascade (E) in fully differentiated
C2C12 myotubes after 2.5 h incubation in medium containing the indicated concentrations of glutamine (n = 8, 1-Way
ANOVA with Bonferroni correction). Data are depicted as mean +SD. *p < 0.05, **p < 0.01, ***p < 0.001.
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ArticleLike MSO treatment, acute exercise, in the form of a 45-min swimming intervention, significantly reduced
glutamine levels in serum in both tumor-free and E0771 tumor-bearing mice. The reduction in serum gluta-
mine of about 30%–40% persisted at least 2 h into the recovery period and was restored to baseline levels
after 24 h. Acute, transient changes in systemic factors, such as catecholamines and myokines, accompa-
nying an acute exercise bout have previously been linked to the anti-cancer effect of exercise (Dethlefsen
et al., 2017). Our current paper suggests the addition of glutamine to the list of factors altered by acute
exercise, which collectively contribute to an environment unfavorable to cancer growth and progression.
In parallel, we found that swimming increased the expression of GS and glutamine transporters in muscle,
whereas regulation in the tumor was less affected by exercise training. In continuation, we found that long-
term training in the form of voluntary wheel running significantly reduced the growth of both LLC and E0771
tumors, and as after the acute swimming intervention, we hardly observed any differential gene expression
in the tumors, wherease transcriptional adaptations did occur in muscle tissue.
Mice with E0771 tumors exhibited significantly reduced intramuscular expression of GS and glutamine
transporters in response to voluntary wheel running, indicative of a long-term adaptive suppression of
muscular expression of GS and glutamine transporters by exercise.
In muscle tissue, LLC tumors induced the mRNA expression of several components of the atrophic
signaling cascade, as has been previously described (Busquets et al., 2012). Voluntary wheel running
completely prevented this tumor-induced expression, in a pattern similar to the effect of MSO. Inhibition
of myostatin signaling has in several mouse studies been shown to prevent tumor-induced cachexia
and prolong survival (Busquets et al., 2012; Zhou et al., 2010). Our findings are in full accordance with
this and extend these previous findings by suggesting that the abolishment of tumor-induced mRNA
expression of atrophy/myostatin in muscle tissue can be obtained by voluntary wheel running, resulting10 iScience 23, 100978, April 24, 2020
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Articlein prevention of tumor-induced weight loss. We did, however, not observe changes in the expression of
atrophic markers on the protein level. In addition to the induced mRNA expression of atrophic markers,
we observed an increased mRNA expression of the glutamine exporter SLC7A5 in the presence of LLC tu-
mors (Baird et al., 2009; Hodson et al., 2018). Considering the dependence of LLC tumors on external
glutamine supply, this might suggest that LLC tumors are able to directly influence glutamine export
from skeletal muscle. It is generally accepted that cachexia-inducing tumors can reprogram the host meta-
bolism in a manner that favors nutrient supply to the tumor at the expense of host tissue wasting (Busquets
et al., 2014; Porporato, 2016). Several tumor models have previously been documented to affect muscle
glutamine synthesis and transport. In rats carrying methylcholanthrene-induced (MCA) fibrosarcoma,
muscular GS activity and expression was increased, glutamine release from muscle increased, and
intramuscular glutamine concentration was reduced (Chen et al., 1993). Likewise, in rats carrying Walker
256 carcinosarcoma, skeletal muscle and plasma glutamine content decreased and release of glutamine
from extensor digitorumlongus (EDL) muscle increased (Parry-Billings et al., 1991). A recent tracer-exper-
iment in mice revealed incorporation of muscle-derived glutamine into subcutaneous C26 tumors, possibly
directly recruited by tumor-derived high-mobility group box 1 (HMGB1) protein release to the circulation
(Luo et al., 2014). Our experiments suggest that voluntary wheel running can counteract this tumor-induced
regulation of glutamine export from skeletal muscle. Glutamine is the most abundant free amino acid in
muscle tissue, estimated to make up more than 40% of the free intramuscular amino acid pool (Bergstro¨m
et al., 1974; Lo¨fberg et al., 2002). Additionally, it is incorporated into proteins, where it may account for
between 4% and 14% of intact muscle protein depending on the mode of estimation (Darmaun et al.,
1988; Kuhn et al., 1999). Assuming that LLC tumors can increase glutamine release from skeletal muscle,
usurping muscular glutamine could be onemechanism by which LLC tumors induce muscle wasting, simply
by depleting the large intramuscular glutamine pool.
The proposition that an effect of exercise could be to starve tumors of a key factor for growth goes well with
recent epidemiological data showing that exercise lowers the risk of cancer across histologies (Moore et al.,
2016). Also, in our study a prominent tumor inhibitory effect was found in two rather different tumor models,
namely a lung cancer model and a triple-negative breast cancer model, in line with glutamine being impor-
tant in tumor growth across histologies (Chiu et al., 2017; Gross et al., 2014; Ha¨fliger et al., 2018; Schulte
et al., 2018). Recent evidence points to a number of effects of exercise that lead to tumor growth inhibition,
as reviewed previously (Hojman et al., 2018), and the current paper adds to the list of factors that may
explain the rather striking findings placing exercise as central in cancer prevention.
We have previously shown that voluntary wheel running can prevent tumor growth across a panel of murine
tumors. In B16 malignant melanoma tumors, we identified a marked exercise-mediated upregulation of
NK-cell infiltration into tumors as an underlying mechanism for exercise-mediated suppression of tumor
growth (Pedersen et al., 2016). In the present study, we did not find any exercise-induced expression of
NK cell markers in LLC tumors (data not shown), underlying that exercise may influence tumor growth by
different pathways dependent on tumor type.
In conclusion, we show that limiting glutamine availability, either pharmacologically or physiologically by wheel
running, decreased tumor growth and reduced mRNA expression of atrophy markers in muscle from tumor-
bearing mice. In continuation, we demonstrated a complete abolishment of LLC-tumor-induced weight loss
by voluntary wheel running, independently of the effect of wheel running on tumor growth.Limitations of the Study
The LLC and E0771 tumor models applied in this project constitute transplantable syngeneic tumor
models. A general limitation inherent to all transplantable tumor models is the bypassing of the initial steps
in tumor development during which cells are transformed and starts neoplastic division. Accordingly, in the
interventions withMSO and voluntary wheel running, potential effects on initial tumor development are not
investigated with this approach. Thus, the present results exclusively represent effects on already trans-
formed tumor cells, their establishment as solid tumors, and subsequent tumor growth.
Swimming and voluntary wheel running were applied as exercise interventions, thus representing both a
forced and a voluntary type. Because the swimming intervention does represent forced exercise it is likely
that a stress response was evoked in themice during the 45min of swimming. Thus, effects of the swimming
intervention cannot necessarily be attributed solely to the exercise component of the intervention. ToiScience 23, 100978, April 24, 2020 11
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Articleavoid subjecting the mice to the stress induced by single housing, mice were housed in pairs. Thus, for the
voluntary wheel running intervention, the LCD Activity Wheel Counters only provide information about the
daily distance covered per cage, whereas the distribution of this distance between two mice in a cage re-
mains unknown. The average distances reported per mouse per day are thus approximations.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
DATA AND CODE AVAILABILITY
The accession number for the RNA-sequencing analysis of LLC tumor tissue reported in this paper is Ar-
rayExpress: E-MTAB-5311. The accession number for the RNA-sequencing analysis of murine muscle tissue
reported in this paper is ArrayExpress: E-MTAB-5974.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.100978.
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FIGURE S1. Volcano plot of RNAseq data from LLC tumors. Related to figure 4 
Volcano plot of intratumoral gene expression obtained by RNA-sequencing of LLC tumors from sedentary (CON) and 
wheel running (EX) C57BL/6 mice (CON = 8, EX = 7). The y and x axes represent significance and log-fold-change, 
respectively. Red color designates genes that are significantly regulated in response to wheel running.  
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FIGURE S2. Volcano plot of RNAseq data from tibialis anterior muscles. Related to figure 6 
Volcano plot of intramuscular gene expression obtained by RNA-sequencing of Tibialis Anterior muscle from sedentary 
(CON) and wheel running (EX) C57BL/6 mice carrying LLC tumors grown to the same size (CON = 10, EX = 14 (samples 
selected based on which mice ran the most)). The y and x axes represent significance and log-fold-change, 
respectively. Red color designates genes that are significantly regulated in response to wheel running. 
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TRANSPARENT METHODS 
ANIMAL STUDIES 
Mice 
Mice were bred locally in the animal facilities using C57BL/6 breeding pairs purchased from Taconic 
Bioscience (Denmark) or Harlan (The Netherlands). For the study with MSO treatment, experimental mice 
were obtained directly from Taconic Bioscience, Denmark. All animal experiments were carried out in 
accordance with the ARRIVE guidelines, and protocols were approved by the Danish Animal Experiments 
Inspectorate. All animal experiments were carried out under controlled temperature and humidity 
conditions in a 12:12-h light-dark cycle. Adult female mice (16 weeks old for the wheel running experiment 
in mice with E0771 breast cancer tumors and aged 8-16 weeks for all other experiments) were housed in 
pairs in standard housing cages with free access to water and food.  
 
Tumor models 
LLC and E0771 tumor cell lines were tested negative for viruses and bacteria, including mycoplasma, by 
RAPIDMAP27-testing. For glutamine deprivation studies, LLC and E0771 cells were grown in RPMI 1640 
culture medium with and without glutamine (ThermoFischer). Cell viability was measured by MTS assay 
with absorbance at 490 nm read in the Multiskan-Ascent ELISA reader (ThermoLabsystems). In 
preparation of tumor inoculations, LLC cells were grown in Dulbecco's Modified Eagle Medium 
(DMEM) (1X), GlutamaxTM (Gibco), and E0771 cells were grown in RPMI 1640 culture medium 
(ThermoFischer). All cells were grown in 10 cm dishes (ThermoScientific) at 37 ͦC and 5% C02, and all media 
were supplemented with 10% fetal bovine serum (FBS) (Gibco) and 1% Penicillin/Streptomycin (P/S) 
(ThermoFischer). For tumor induction, LLC cells were inoculated subcutaneously at the flank (2.5*105 cells 
in 100 µl PBS/mouse). E0771 cells were inoculated in the mammary fat pad (1*105 cells in 100 µl 
PBS/mouse). For the wheel running and MSO studies, LLC and E0771 tumors were allowed to develop for 2-
3 weeks before excision. Tumor size was determined by weight and by volume using the calculation 
V=d1*d2*d3*π/6, where d is the diameter of the tumor. For the swimming experiment, E0771 tumors grew 
for 16 days before the swimming intervention.  
 
MSO treatment 
For the MSO experiments, mice received intraperitoneal injections of L-Methionine Sulfoximine, (M5379, 
Sigma) or saline from 2 weeks before tumor cell inoculation and until termination. MSO was dissolved in 
0.9% saline and administered intraperitoneally 3x/week (Mondays, Wednesdays and Fridays) at a dose of 
20 mg/kg mouse.  
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Exercise interventions 
For the voluntary wheel running intervention, running wheels (Starr Life Sciences) of 12 cm in diameter 
were installed in the home cages from 4 weeks before tumor cell inoculation and throughout the 
experiment. Both mice from one cage could run in a wheel simultaneously. Running distance was measured 
daily by LCD Activity Wheel Counters (Starr Life Sciences), and cages that did not exceed 0.5 km/day/mouse 
were excluded from the exercise groups.   
 
For the swimming interventions, mice were placed in a 35˚C water basin to swim for 45 min as a model of 
acute exercise. For baseline blood samples, mice had blood drawn from the jaw and were given a resting 
period of 5 min before swimming. Subsequent blood samples were drawn either from the jaw (Fig. 3A) or 
from the neck after sacrifice (Fig. 3B). 
 
DXA scanning 
Fat mass (FM) and lean body mass (LBM) were determined using a LUNAR iDXA dual-energy X-ray 
absorptiometry (DXA) scanner (GE Healthcare Systems, LUNAR, Madison WI) with the “small animal” 
software application (acquisition software version 14.10.022 and analysis version 17). Mice were 
anaesthetized (Hypnorm/Dormicum, 0.1ml/10g) and placed side-by-side on the scan table. Each group of 
mice was scanned 5 consecutive times. Regions of interest (ROIs) for analysis of whole-body composition 
were manually adjusted once around each mouse and then copied to following scans. An overall threshold 
level for separation of bone from soft tissue was determined visually and kept for all scans in order to 
enable determination of relative changes in body composition. Median FM and LBM for each mouse were 
then calculated. 
 
CELL LINES AND IN VITRO STUDIES 
Differentiation and stimulation of C2C12 myotubes 
Undifferentiated myoblasts were grown in Matrigel-coated dishes in growth medium (DMEM (1X) 
Glutamax (Gibco) supplemented with 20% FBS (Gibco), 1% Fungizone (Invitrogen) and 1% P/S 
(ThermoFischer)). At 90-100% confluence growth medium was substituted with differentiation medium 
(DMEM (1X) Glutamax (Gibco) supplemented with 2% HS (Gibco) and 1% P/S. Differentiation medium was 
replaced every day by removal of 90% of the old differentiation medium and addition of the same volume 
of fresh differentiation medium. For formation of fully differentiated myotubes for stimulation with 
myostatin and glutamine, differentiation proceeded for 7 days.  
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For incubation with myostatin, fully differentiated C2C12 myotubes were incubated for 2.5 h in normal 
differentiation medium with and without 400 ng/ml recombinant Myostatin (R&D Systems). For 
incubations in different glutamine concentrations, fully differentiated C2C12 myotubes were incubated for 
2.5 hours in normal differentiation medium as described above (3.9 mM Glutamine) or in glutamine-free 
medium (DMEM (Gibco) supplemented with 2% HS and 1% P/S) with and without supplementation of 
0.5mM L-Glutamine (Gibco). For incubation of differentiating myotubes in cancer cell conditioned medium, 
myotubes were differentiated under normal conditions for 96 hours as described above. Subsequently, 
differentiation was continued for 72 hours in medium containing 25% preconditioned medium from LLC cell 
cultures 
 
Generation of LLC cell-conditioned medium 
LLC cells were grown in DMEM) (1X), GlutamaxTM (Gibco), supplemented with 10% FBS and 1% P/S). 
Medium conditioned for 48h was collected and spun at 1000 G for 5 minutes (ROTOFIX 32A, Hettich 
Labinstrument ApS) to remove cell debris. Conditioned medium was mixed 1:4 in fresh C2C12 
differentiation medium and added to myotubes as described above. The concentration of LLC cells when 
conditioned medium was collected was 651*103 cells/ml as measured on the CountessTM II FL Automated 
Cell Counter.  
 
Fluorescence Microscopy 
C2C12 myotubes were fixed and permeabilized using the Image-iT Fixation/Permeabilization Kit (Molecular 
Probes) and incubated with primary antibody for 1 hour at RT (1:50 Primary Anti-Sarcomeric Alpha Actinin 
antibody [EA-53] (ab9465) in Hanks Balanced Salt Solution (HBSS).  Myotubes were washed 3x5 minutes in 
Dulbecco’s Phosphate-Buffered Saline (DPBS) followed by incubation with secondary antibody (Alexa Flour 
Secondary antibodies (Molecular probes) under a lid for 30 minutes at room temperature.  Myotubes were 
washed 3x5 minutes in DPBS before fluorescence microscopy in the EVOS FL (Thermo Fisher). 
 
METHOD DETAILS 
Serum glutamine measurements 
Serum was generated by incubation of fresh blood samples at room temperature for 30 minutes, followed 
by centrifugation for 10 min at 3000 G at 4 °C. Glutamine was measured using the ENZYChromTM Glutamine 
Assay Kit (EGLN-100) (Bioassay Systems).  
 
RNA isolation, cDNA synthesis and RT-qPCR  
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Upon excision, tumor and muscles were snap frozen in liquid nitrogen, and stored at -80°C. Before RNA 
extraction, frozen tumors were pulverized on dry ice using mortar and pestle. RNA was isolated from 
muscle and tumor tissue, or C2C12 myotubes by Ambion™ TRIzol™ Reagent (Invitrogen) according to 
manufacturer’s instructions, dissolved in Ultrapure Nuclease free water (Life Technologies) and stored at -
80˚C until further use. RNA concentration and purity were measured on Nanodrop 1000 
spectrophotometer (Thermo Scientific). Each sample was diluted to a final concentration of 25 ng/µl in a 
total volume of 10 µl Ultrapure Nuclease free water. Complementary DNA (cDNA) was synthesized using 
the High-Capacity cDNA Reverse Transcription Kit (Life Technologies) in the S1000TM Thermal Cycler 
(BioRad), diluted with Ultrapure Nuclease free water to a final volume of 200 µl and stored at -20 ͦC. For RT-
qPCR, samples were loaded in triplicates onto MicroAmp® Optical 384-Well Reaction Plates (Life 
Technologies), spun at 1000 G for 2 minutes in the (SIGMA 4-16KS bench centrifuge) and cDNA templates 
were amplified in the WiiA7 real-time PCR machine (Applied Biosystems) with either SYBR Green (PowerUp 
SYBR® Green PCR Master Mix, Applied Biosystems) or TaqMan (TaqMan®Universal PCR Master Mix, Applied 
Biosystems) master mix. Data was quantified using the delta/delta CT method, and expression levels of 
target genes were normalized to the reference genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
for muscle tissue or peptidylprolyl isomerase A (PPIA) for tumor tissue.   
 
Murine primer sequences applied 
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RNA-sequencing analysis 
RNA-seq was performed both on tumor and muscle tissues. In the latter case, all 10 mice from the tumor 
group were used, and the 14 mice having covered the most distance in the running wheels were selected 
from the Tumor + EX group.  RNA was isolated from muscle and tumor tissue by Ambion™ TRIzol™ Reagent 
(Invitrogen). Sequencing libraries were prepared from 1μg total RNA using the TruSeq stranded mRNA 
library preparation kit (Cat# RS- 122-2101/2102, Illumina Inc.) including polyA selection. The library 
preparation was performed according to the manufacturers’ protocol (#15031047). Sequencing was 
performed on HiSeq2500, paired-end 125bp read length with v4 sequencing chemistry. The following 
bioinformatics pipeline was adopted, as recommended by the sequencing facility. RNA-seq reads were 
trimmed for adapters using TrimGalore (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore), 
aligned to GRcm38 ENSEMBLE Mus musculus genome using STAR (Dobin et al., 2013) and counted using 
featureCounts (Liao et al., 2014). Quality control (QC) was performed using MultiQC (Ewels et al., 2016) to 
check parameters such as frequency of duplicated reads, fraction of unaligned reads, saturation of known 
and number of unknown splice variants. Samples with <70% of reads aligned were considered of 
insufficient quality. Deposition of data: RNA-seq data related to tumor and muscle tissues were deposited 
in ArrayExpress: E-MTAB-5311 and ArrayExpress: E-MTAB-5974,  respectively. 
 
Differential gene expression and pathway analysis 
For differential gene expression analysis, genes with less than 10 counts across the dataset were discarded. 
Read counts were normalized according to the library size into size-adjusted log-cpm (counts-per-million). 
Differential gene expression analysis was performed by fitting a weighted linear model to samples 
belonging to the two groups using voom and limma (Law et al., 2014). Genes differentially expressed at a 
false discovery rate (q) < 0.05 were considered statistically significant. In the case of tumor tissues, for 
which 15 of 16 samples passed QC, genes differentially expressed at a false discovery rate (q) < 0.15 were 
considered statistically significant. Pathway analysis was performed through multiple runs of gene-set 
analyses using piano R-package (Väremo et al., 2013). Mus musculus genes were converted 1-to-1 to human 
genes by homology. Ambiguous annotations were discarded (~66%). Hallmark pathways and Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathways were used as gene-set collections as retrieved in the 
Molecular Signatures Database (MSigDB) (Liberzon et al., 2015).  
 
Western Blotting 
Frozen muscle-samples were homogenized with a metal bullet in MG-buffer (10 % Glycerol, 20 mM Na-
Pyrophosphate, 150 mM NaCl, 50 mM HEPES (pH 7,5) 1% NP-40, 20 mM β-glycerophosphate, 2 mM 
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Na3VO4, 10 mM NaF, 2mM PMSF (Isopropanol), 1 mM EDTA (pH 8), 1 mM EGTA (pH 8), 10 µg/ml Aprotinin, 
10 µg/ml Leupeptin, 3 mM Benzamidine in dd-H20) in a Qiagen Tissue-lyser. The homogenate was rotated 
over end for 1h at 4 ᵒC and centrifuged for 30 min at 17500 g at 4 ᵒC. The supernatant was transferred to 
fresh Eppendorf-tubes, and protein concentration of the lysate was determined using PIERCE BCA Protein 
assay kit #23225. 
Samples were diluted 3:1 in 4X Laemmli sample buffer containing 10% β-mercaptoethanol, and boiled for 5 
min at 95 ᵒC. Samples were separated by SDS PAGE on Criterion TGX Stain-free Precast Gels (Bio-Rad), 
transferred onto PVDF membranes (Trans-blot Turbo Transfer Pack, 0.2 um PVDF, Bio-Rad), blocked in 5% 
skimmilk in TBST 1h at RT and incubated with primary antibodies in 5% skimmilk in TBST ON at 4 ᵒC.  
Membranes were washed 3x10 min in TBST before incubation with secondary antibody diluted in 5% 
skimmilk in TBST for 1h at RT, and imaged by the ChemiDoc Imaging System (Bio-Rad) after incubation with 
Lumina Forte Western HRP Substrate (Millipore) for 3-5 minutes. Bands were quantified using Image Lab 
software. The signal for the protein of interest in each lane was normalized to the total protein amount in 
the same lane visualized by fluorescent detection of proteins within the Criterion Stain Free gels.         
Primary antibodies: Goat-anti-MuRF1/TRIM63 (AF5366, R&D systems, 1:1000), rabbit-anti-Fbx32 
(ab168372, Abcam, 1:1000), rabbit-anti-GLUL (D2O3F #80636, Cell Signaling, 1:1000), mouse-anti-SNAT3 
(H-11), sc-398982, Santa Cruz, 1:1000). Secondary antibodies: Polyclonal Goat-anti-Rabbit immunoglobulins 
HRP (DAKO, 1:5000), Polyclonal Rabbit-anti-Mouse immunoglobulins HRP (DAKO, 1:5000), Polyclonal 
Rabbit-anti-Goat immunoglobulins HRP (DAKO, 1:500). 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Statistical analyses (excluding RNAseq data) were performed using GraphPad Prism 7 Software. Differences 
between groups were analyzed for significant differences using paired and unpaired Student’s t-tests and 
One-way and Two-way ANOVAs. Data in graphs represent mean +/- standard deviations, and p-values 
below 0.05 were considered significant. *p<0.05, **p<0.01, ***p<0.001. 
 
DATA AND CODE AVAILABILITY 
The accession number for the RNA-sequencing analysis of LLC tumor tissue reported in this paper is 
ArrayExpress: E-MTAB-5311. The accession number for the RNA-sequencing analysis of murine muscle 
tissue reported in this paper is ArrayExpress: E-MTAB-5974. 
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KEY RESOURCES TABLE 
 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Primary Anti-Sarcomeric Alpha Actinin antibody [EA-53] Abcam ab9465 
   
Bacterial and Virus Strains  
None   
   
Biological Samples   
None   
   
Chemicals, Peptides, and Recombinant Proteins 
L-Methionine Sulfoximine Sigma Aldrich Cat#: M5379 
Myostatin R&D Systems Cat#: 788-G8-010 
   
Critical Commercial Assays 
ENZYChromTM Glutamine Assay Kit Bioassay Systems EGLN-100 
High-Capacity cDNA Reverse Transcription Kit Life Technologies Cat#: 4368814 
PowerUp SYBR® Green PCR Master Mix Applied Biosystem Cat#: A25780 
TaqMan®Universal PCR Master Mix Applied Biosystems Cat#: 4304437 
  
 
TruSeq stranded mRNA library preparation kit  Illumina Inc. RS- 122-2101/2102, 
 
Deposited Data 
RNA-seq data related to tumor were deposited in 
ArrayExpress with project ID E-MTAB-5311 
  
RNA-seq data related to muscle tissues were deposited 
in ArrayExpress with project E-MTAB-5974 
  
   
Experimental Models: Cell Lines 
Lewis Lung carcinoma ATCC Cat#: ATCCÒ CRL-
1642 
E0771 breast cancer cell line CH3 Biosystems Cat#: 940001 
   
   
   
Experimental Models: Organisms/Strains 
C57Black/C mice Taconic N/A 
   
Oligonucleotides 
Please see Table S3 for PCR primers   
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Recombinant DNA 
None   
   
Software and Algorithms 
Body composition with the “small animal” software 
application (acquisition software version 14.10.022 and 
analysis version 17) 
GE Healthcare 
Systems, LUNAR, 
Madison WI 
N/A 
   
Other 
Running wheel (12 cm) Starr Life Science N/A 
LCD Activity Wheel Counters Starr Life Science N/A 
   
 
 
 
 
 
 
 
 
 
 
 
 
